Search
Breast MRI and Advanced Breast Intervention
Bonnie Joe, MD, PhD, discusses how breast MRI is performed, common indications for breast MRI and advanced methods for biopsy and pre-surgical localization of tumors.UCSF500 Cancer Gene Panel Test
The UCSF500 Cancer Gene Panel leverages world-class expertise for advanced cancer cases. Designed by our leading cancer specialists, the UCSF500 offers unparalleled depth and precision in genetic analysis.Lung Cancer Screening: Who, How and When to Refer
†horacic radiologist Brett M. Elicker, MD, and thoracic surgeon Johannes Kratz, MD, present about current lung cancer screening guidelines: who, how, and when to refer.Screening Guidelines for Common Cancers: A Lifesaving Update
In just 35 minutes, hematologist-oncologist Akshiv Malhotra, MD, presents the current recommendations on cervical, breast, colon and lung cancers, breaking down the test options for each and when to start tests based on a patient’s risk.Immune Cells Leave Fingerprints on Tumors Metastasized to the Brain Offering Clues to Future Therapies
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types. Their findings, published the February 17 issue of CELL, provide a potential roadmap for metastatic tumor formation that could be used to design therapies to improve the treatment of metastasized patients.Cancer Preventive Care: Empower Your Patients to Take Small-But-Significant Steps
Patients worry about cancer but struggle to make lifestyle changes. Here’s how to discuss factors they can control and realistic steps they can take.Sneaky Senescent Cells That Resist Cancer Treatment Can Provide Druggable Lung Cancer Target
Senescent fibroblasts are aging cells that no longer divide and protect against tumor development.International Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 63rd Annual Meeting and Exposition. This year’s meeting will be held in Atlanta, Georgia – and virtually – from December 11-14, 2021.UCSF’s Lawrence Fong, MD, Earns NCI Award for Cancer Immunotherapy Research
The National Cancer Institute (NCI)has honored Lawrence H. Fong, MD, leader of the UC San Francisco Cancer Immunotherapy Program, with an Outstanding Investigator Award (R35).These awards support investigators who have significant records of productivity in cancer research with multiyear funding for projects of exceptional potential.Inclusion of New Risk Factors Can Improve Prediction of Invasive Breast Cancer
UCSF researchers update Breast Cancer Surveillance Consortium model to account for BMI and other familial risk factors.UCSF Surgical Oncologists Providing New Treatment Options for Patients with Metastatic Gastrointestinal Cancers
UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.Screening for Cervical Cancer: New Evidence on Options and Outcomes
Gynecologic oncologist Megan Swanson, MD, MPH, deciphers recent changes to cervical cancer screening guidelines and uses the data to illuminate the relative value of test options – Pap smears, detection of high-risk HPV strains, or both tests together.Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies
Using data from over 300 patient tumors, UCSF researchers have described 12 classes of “immune archetypes” to classify cancer tumors. Their findings, published today in CELL, reveal that cancers from different parts of the body are immunologically similar to one another. These classifications provide unique strategies for enhancing each patient’s choice of cancer immunotherapies.Katherine Van Loon Named Editor-in-Chief of JCO Global Oncology
Katherine Van Loon, MD, MPH, has been appointed as the next editor-in-chief of JCO Global Oncology (JCO GO), an American Society of Clinical Oncology (ASCO) journal.UCSF Surgeons Perform First Pure Robotic Whipple Surgery in the Bay Area
Gastrointestinal surgeons at UC San Francisco have performed the first pure robotically assisted Whipple surgery in San Francisco.UCSF Osher Center Overview: Integrative Medicine’s Value for Providers and Patients
Sanford C. Newmark, MD, medical director of the UCSF Osher Center for Integrative Medicine, explains what integrative medicine is (hint: it’s neither “alternative medicine” nor homeopathy) and how referred patients can benefit from its proven techniques.Cardio-Oncology & Immunology: Specialized Cardiovascular Care for Cancer Patients
Led by a multidisciplinary team of specialists and researchers, our program optimizes the cardiovascular health of cancer patients and cancer survivors.High Risk for Breast Cancer: Methods and Schedules to Ensure Optimal Screening
Hematologist-oncologist Elham Vosoughi, MD, starts with an update on breast cancer stats, noting that incidence in the United States is increasing by 1% every year – with an even sharper rise for women under 50.UCSF Clinic Fills Unmet Need for Managing Oral Side Effects of Cancer Therapies
As advances in cancer treatments have expanded, so has the number of side effects that impact the mouth. Oral medicine specialists at UC San Francisco are working to mitigate these often-debilitating problems, which affect the majority of patients undergoing or recovering from cancer therapy.Genomic Sequencing Is Changing Diagnosis, Treatment for Patients with Brain Cancer
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation and chemotherapy.Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New data from a clinical trial show therapies may activate lymph nodes to produce tumor-tackling T cells.UCSF Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.Study Finds Significant Chemical Exposures in Women With Cancer
In a sign that exposure to certain endocrine-disrupting chemicals may be playing a role in cancers of the breast, ovary, skin and uterus, researchers have found that people who developed those cancers have significantly higher levels of these chemicals in their bodies.UCSF Urology Experts Highlight Leadership in Innovative Research and Treatment at National Urology Conference
Using artificial intelligence (AI) to improve prediction of prostate cancer treatment response and biomarkers to enhance prostate cancer diagnosis were among the topics discussed by UCSF clinicians at the American Urological Association’s 2025 annual meeting.